Biome Australia (BIO) investor relations material

Mission and market position

• Aims to prevent disease, improve health outcomes, and make products widely accessible, operating as a certified B Corporation.

• Recognized as Australia's fastest-growing probiotic brand, leading by revenue in community pharmacy and holding the top growth position in the largest pharmacy chains.

• Operates two clinically-backed brands, Activated Probiotics and Activated Therapeutics, with over 30 randomized controlled trials supporting product efficacy.

Financial performance and growth

• Achieved record FY26 revenue of $23.9m, up 30% year-on-year, with adjusted EBITDA of $2.0m and pre-tax net profit of $1.2m, a 453% increase.

• Gross margin rose to 62.1%, with ten consecutive EBITDA-positive quarters and strong operating leverage.

• Revenue has compounded at ~75% annually since FY20, with international revenue reaching $1.8m in FY26.

Strategic initiatives and operational highlights

• Onshore manufacturing begins in FY27, expected to lift gross margin above 65% and improve working capital efficiency.

• Signed exclusive cross-border e-commerce agreement for China, targeting launch within FY27, leveraging Australian-made credentials.

• BMB18 proprietary strain is in a 240-participant human clinical trial, with results anticipated in FY27.